ReviewPharmaceutical biology2019
Phytotherapy in treatment of Parkinson's disease: a review.
Review in Pharmaceutical biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 91 citations in OpenAlex.
- Exploring the Neuropharmacological Potential of Ligustrum sinense Relevant to Parkinson's Disease: In Vivo and In Silico Study.Chemistry & biodiversity · 2026Article
- Resveratrol-Loaded Polymeric Nanoparticles Protect Against Rotenone-Induced Parkinsonian-Like Cellular Damage In Vitro: Association with NRF2/HMOX-1 Expression Changes.Neurochemical research · 2026Article
- Neuroprotective potential of Bilacunaria microcarpa extracts in Mpp+ induced SH-SY5Y cell model of Parkinson's disease.Molecular biology reports · 2026Article
- Tailoring treatments: pharmacogenomics in the management of neurodegenerative diseases.Acta neurologica Belgica · 2026Review
- Chicoric acid prevents motor dysfunction in zebrafish Parkinson's disease model through Nrf2-mediated antioxidant effect.BMC complementary medicine and therapies · 2026Article
- Ceftriaxone's Multifaceted Neuroprotection in Parkinson's Disease: Preclinical Evidence and Implications for Drug Repurposing.Drug design, development and therapy · 2026Review
- Innovative approach in Parkinson's targeting via berberine-loaded mucoadhesive surface-modified liposomes: a multi-faceted study.BMC pharmacology & toxicology · 2025Article
- Neurogrit Gold Attenuates 6-OHDA-Induced Dopaminergic Neurodegeneration in Parkinson's Model of Caenorhabditis elegans by Reducing α-Synuclein Accumulation and Pink/Pdr-1 Driven Mitochondrial Dysfunction.CNS neuroscience & therapeutics · 2025Article
- Structural Insights into the Dynamics of Water in SOD1 Catalysis and Drug Interactions.International journal of molecular sciences · 2025Article
- Potential therapeutic effects of curcumin, with or without L-DOPA, on motor and cognitive functions and hippocampal changes in rotenone-treated rats.Metabolic brain disease · 2025Article
- Neuroprotective effect of cedrol in a male rat model of Parkinson's disease.Physiological reports · 2025Article
- Congrong Shujing Granules ameliorates mitochondrial associated membranes to against MPPFrontiers in pharmacology · 2025Article
- An Integrative Computational Approach for the Identification of C-Abl Kinase Inhibitors from Anti-Parkinson Plant-Derived Bioactive.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025Article
- Strategies in Parkinson's Disease Therapeutics - A Need for Synergy of Ayurveda, Small Molecules and Nanoparticles aided Approaches.Current topics in medicinal chemistry · 2025Review
- The molecular determinants of calcium ATPase inhibition by curcuminoids.Biochimica et biophysica acta. Biomembranes · 2024Article
- Natural Compounds That Activate the KEAP1/Nrf2 Signaling Pathway as Potential New Drugs in the Treatment of Idiopathic Parkinson's Disease.Antioxidants (Basel, Switzerland) · 2024Review
- Principal Component Analysis (PCA) of Molecular Descriptors for Improving Permeation through the Blood-Brain Barrier of Quercetin Analogues.International journal of molecular sciences · 2023Article
- Emerging Role of Plant-Based Bioactive Compounds as Therapeutics in Parkinson's Disease.Molecules (Basel, Switzerland) · 2023Review
- Review
- Characterization and In Vivo Antiangiogenic Activity Evaluation of Morin-Based Cyclodextrin Inclusion Complexes.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.